Report Description
A recent market
intelligence report that is published by Data Insights Partner on the global Plasma
Fractionation market makes an
offering of in-depth analysis of segments and sub-segments in the regional and
international Plasma Fractionation market. The research
also emphasizes on the impact of restraints, drivers, and macro indicators on
the regional and global Plasma Fractionation market over the short as well as long period of time. A detailed
presentation of forecast, trends, and dollar values of global Plasma
Fractionation market is offered. In
accordance with the report, the global Plasma Fractionation market is projected to expand at a CAGR of 7% over the period of forecast.
Market Insight, Drivers, Restraints&
Opportunity of the Market:
Plasma
fractionation is the process which separates of blood components from blood
plasma. Million of liters of plasma (raw
materials) is required annually to produce plasma derived products. Some of the
plasma are obtained by separating plasma from red blood cells after whole blood
donation, for example at a blood donation camp. This plasma is known as
“recovered plasma” because the target of the blood donation camps is to get red
cells, platelets and plasma (by products). Another type of plasma is known as
source plasma which is achieved from specialized plasma donation center through
plasmapheresis instrument (which obtains the whole blood from the donor, keep
the plasma and return the red cells to the donors).Nowadays, top three
companies (CSL Plc, Grifols, and Baxter) in the global plasma fractionation
industry collects around 80% of the source plasma in the U.S. Currently, the
plasma collection centers in the U.S. have grown to around 650 in 2017 from 550
in 2015, which indicates the demand of plasma derived medicines. A similar
trend of demand of plasma derived medicines, and the growth of plasma
collection centers have been observed in Europe. Although, China has huge
demands of plasma or production of plasma derived medicines, the collection
centers in China can’t meet the annual requirements.
The global Plasma
Fractionation market is primarily driven by the growing geriatric population
and increasing use of immunoglobulin’s in therapeutics areas. In addition, increasing
cases of complicated diseases and growth of plasma collection would also propel
the growth of the global Plasma Fractionation market in the upcoming period. Conversely,
stringent Regulatory Landscape and pricing pressure would likely to restrain
the global Plasma Fractionation market during the forecast period. Currently major companies express their
concerns about the growing pricing pressure in Europe and North America. Higher
price is due to the increasing raw material cost, cost of products and
inventory used for production of plasma derived proteins. According to the
annual report of China Biologic, the cost of raw material is about to 80% of
the total inventory cost. However, technological advancement and new product
development, strategic alliance among key companies will provide the global Plasma
Fractionation market to provide an opportunity to propel in the upcoming
future.
Segment Covered:
This market
intelligence report on the global Plasma Fractionation market encompasses
market segments based on product type, application and end user. On the basis
of product type, the sub-market is classified into Polyvalent IVIG, Polyvalent
IVIG/SCIG, Factor VIII, Factor IX, PCC, Fibrinogen Concentration, Factor XIII, VWF,
Albumin, Fresh Frozen Plasma and Others. In terms of application, the global
Plasma Fractionation market is categorized into neurology, immunology,
hematology, critical and others. Based on end user, the global Plasma
Fractionation market has been segregated into Hospitals, Biotechnology and Pharmaceutical
Industry, Clinical Research Laboratories and Others. By Geography, the global Plasma
Fractionation market has been divided into North America (the U.S., Canada),
Latin America (Brazil, Mexico, Argentina and other countries), Europe (Germany,
France, the U.K., Spain, Italy, Russia, and other countries), Asia Pacific
(India, Japan, China, Australia and New Zealand and other countries), Middle
East and Africa (GCC, South Africa, Israel and Other countries).
Profiling of Market
Players:
This business
intelligence reportoffers profiling of reputed companies that are operating in
the market. Companies such as CSL Limited, Griifols, S.A., Baxter, Octapharma,
Kedrion S.p.A , Biotest AG, Albumedix
China Biologic Products Holdings, Inc, The LFB
Group and others have been profiled into detail so as to offer a glimpse of the
market leaders. Moreover, parameters such as Plasma Fractionation related
investment & spending and developments by major players of the market are
tracked in this global report.
Report Highlights:
In-depth
analysis of the micro and macro indicators, market trends, and forecasts of
demand is offered by this business intelligence report. Furthermore, the report
offers a vivid picture of the factors that are steering and restraining the
growth of this market across all geographical segments. In addition to that, IGR-Growth
Matrix analysis is also provided in the report so as to share insight of the
investment areas that new or existing market players can take into consideration.
Various analytical tools such as DRO analysis, Porter's five forces analysis
has been used in this report to present a clear picture of the market. The
study focuses on the present market trends and provides market forecast from
the year 2017-2027. Emerging trends that would shape the market demand in the
years to come have been highlighted in this report. A competitive analysis in
each of the geographical segments gives an insight into market share of the
global players.
Salient Features:
Ø
This study offers
comprehensive yet detailed analysis of the Plasma Fractionation market, size of the market (US$ Mn), and Compound Annual Growth
Rate (CAGR (%)) for the period of forecast: 2019 – 2027, taking into account
2018 as the base year
Ø
It explains upcoming
revenue opportunities across various market segments and attractive matrix of
investment proposition for the said market
Ø
This market
intelligence report also offers pivotal insights about various market opportunities,
restraints, drivers, launch of new products, competitive market strategies of
leading market players, emerging market trends, and regional outlook
Ø
Profiling of
key market players in the world Plasma Fractionation market is done by taking into account various parameters such as
company strategies, distribution strategies, product portfolio, financial
performance, key developments, geographical presence, and company overview
Ø
Leading
market players covered this report comprise names such as CSL Limited, Griifols, S.A., Baxter, Octapharma, Kedrion
S.p.A , Biotest AG, Albumedix, China Biologic Products Holdings, Inc, The LFB
Group and among others
Ø
The data of
this report would allow management authorities and marketers of companies alike
to take informed decision when it comes to launch of products, government
initiatives, marketing tactics and expansion, and technical up gradation
Ø
The world
market for Plasma Fractionation caters to the needs
of various stakeholders pertaining to this industry, namely suppliers, manufacturers,
investors, and distributors for Plasma Fractionation market. The research
also caters to the rising needs of consulting and research firms, financial
analysts, and new market entrants
Ø
Research
methodologies that have been adopted for the purpose of this study have been
clearly elaborated so as to facilitate better understanding of the reports
Ø
Reports have
been made based on the guidelines as mandated by General Data Protection
Regulation
Ø
Ample number
of examples and case studies have been taken into consideration before coming
to a conclusion
Reasons to buy:
v
Identify
opportunities and plan strategies by having a strong understanding of the
investment opportunities in the Plasma Fractionation market
v
Identification
of key factors driving investment opportunities in the Plasma
Fractionation market
v
Facilitate
decision-making based on strong historic and forecast data
v
Position
yourself to gain the maximum advantage of the industry’s growth potential
v
Develop
strategies based on the latest regulatory events
v
Identify key
partners and business development avenues
v
Respond to
your competitors’ business structure, strategy and prospects
v
Identify key
strengths and weaknesses of important market participants